Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Echinops cephalotes hydroalcoholic extract** is a plant-derived botanical extract prepared from *Echinops cephalotes* and studied primarily as an academic research compound rather than a commercial pharmaceutical asset. In preclinical Alzheimer's disease models, particularly scopolamine-induced memory impairment in mice, the extract has shown cognition-improving activity associated with anti-cholinesterase and anti-butyrylcholinesterase effects, consistent with enhancement of central cholinergic signaling. Reported studies evaluated oral doses such as 25, 50, and 100 mg/kg in mice. Beyond neurocognitive research, extracts of *Echinops cephalotes* have also been investigated experimentally for antidiabetic, cardioprotective, and antifungal properties, but there is no identified branded product, commercial manufacturer, or named company-led development program for this specific hydroalcoholic extract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echinops cephalotes hydroalcoholic extract.